Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Servier"


5 mentions found


Cybersecurity Workers Demand Higher Salaries
  + stars: | 2023-03-28 | by ( Catherine Stupp | ) www.wsj.com   time to read: +6 min
Cybersecurity chiefs are struggling to find employees they can afford, as sought-after job seekers ask for higher salaries. Challenging economic conditions have added a new layer of difficulty for companies around the world that have grappled with a growing shortage of cybersecurity workers. Multinationals including McDonald’s Corp. are seeking more cybersecurity job applicants, including people from nontraditional backgrounds, by removing cyber certifications and degree requirements from many job listings. Newsletter Sign-up WSJ Pro Cybersecurity Cybersecurity news, analysis and insights from WSJ's global team of reporters and editors. In Europe, with companies competing for a small pool of cybersecurity workers, job seekers are looking for flexible work conditions in addition to higher salaries.
Much as he would have liked to significantly increase supplies, Biosca-Reig said he couldn't justify investing millions of euros in new production lines unless he was paid more for the generic drug to cover sharply rising costs. European generic drugmakers say the tender system and regulated prices have fuelled a race to the bottom, and European firms are being undercut by suppliers from Asia. BRUSSELS, WE HAVE A PROBLEMThe European Medicines Agency (EMA) and European Union lawmakers acknowledge there is a problem. Half the generic medicines sold in Spain are priced below 1.60 euros per box or bottle, the country's generics manufacturing association said. But companies with smaller market shares, such as Israel's Teva (TEVA.TA), which has 5% of the region's amoxicillin market according to Medicines for Europe, are constrained.
French drug company Servier launches Mediator appeal
  + stars: | 2023-01-09 | by ( ) www.reuters.com   time to read: +1 min
Companies Servier Laboratories Ltd FollowPARIS, Jan 9 (Reuters) - French drugmaker Servier on Monday launched its appeal against manslaughter and deception convictions handed down by a Paris court in 2021 in connection with weight-loss pill Mediator. The company was fined 2.7 million euros ($2.88 million) for concealing Mediator's risks, and ordered to pay more than 180 million euros in compensation and interest to victims. Servier is appealing more than half a dozen convictions against the company and former head of operations Jean-Philippe Seta, including for manslaughter with wilful misconduct, involuntary injury, fraud and deception. "Servier Laboratories and Jean-Philippe Seta still refute having deliberately deceived patients and their prescribing doctors over the dangers of Mediator," Francois De Castro, a lawyer for the company, told AFP ahead of the appeal. ($1 = 0.9373 euros)Writing by Richard Lough, Editing by Dominique Vidalon and Jane MerrimanOur Standards: The Thomson Reuters Trust Principles.
Firma franceză Servier a primit amendă pentru vânzarea medicamentului Mediator, un medicament pentru slăbit care ar fi cauzat moartea a sute de oameni, relatează agerpres.ro.Firma Servier trebuie să plătească 2,7 milioane de euro (3,17 milioane de dolari) şi a fost găsit vinovată de înşelăciune în formă agravantă, vătămare corporală prin neglijenţă şi omor, a decis luni un tribunal din Paris.Un fost manager al firmei a primit, de asemenea, o condamnare cu suspendare de patru ani. În plus, victimele vor primi în total160 de milioane de euro, reprezentând daune.De asemenea, departamentul a fost amendat cu 300.000 de euro pentru că nu a retras medicamentul de pe piaţă în timp util, deşi efectele sale adverse erau cunoscute, a decis judecătorul.Pastilele, care nu mai sunt vândute în Franţa, ar fi afectat sistemul cardiovascular. Servier a negat întotdeauna aceste afirmaţii.Mediator a fost lansat pe piaţă iniţial ca medicament pentru diabet, în anii '70, dar a fost adesea prescris şi pentru cure de slăbire
Persons: Servier Locations: Franţa
Французскую фармкомпанию Servier признали виновной в сокрытии опасных побочных эффектов у препарата для контроля веса, из-за которых погибли несколько сотен человек. Бывший топ-менеджер Servier Жан-Филипп Сета получил четыре года условно, а компания выплатит почти 3 млн евро штрафа. Препарат связывают со смертью по меньшей мере 500 человек, но по данным независимых исследований, реальное число жертв может быть в несколько раз больше. После громкого скандала Servier согласилась выплатить компенсации пострадавшим на общую сумму в 132 млн евро. Сторона обвинения запрашивала наказание для компании в 10 млн евро за то, что она сознательно скрывала побочные свойства препарата.
Persons: Servier, Le Figaro, Сета Organizations: ЖанФилипп, Национальное агентство по безопасности лекарственных средств () Locations: Париж, Франция
Total: 5